Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

TARRYTOWN, N.Y., Nov. 8, 2021 /PRNewswire/ -- Single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction previously reported during month 1 During the 8-month assessment period there were 0 hospitalizations for COVID-19 in the REGEN-COV group and 6 in the placebo group The fully human antibodies in REGEN-COV were developed to provide long-lasting protective effects without any artificial mutations or sequences Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced additional positive results from a Phase 3 trial jointly run with the National Institute of Allergy and Infectious Diseases (NIAID), which assessed use of a single dose of investigational REGEN-COV® (1,200 mg administered via 4 subcutaneous injections) to prevent COVID-19 in uninfected individuals.

New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19

Merck

Moderna

Pfizer jumped 8% Friday morning, while Moderna dropped 17.8%, Regeneron 6.2% and Merck 9%.

Billions Wiped From Covid Pharma Heavyweights—Including Moderna, Regeneron, Merck—As Pfizer's Antiviral Pill Triggers Selloff

The big biotech delivered an exceptionally strong performance in Q3.

3 Reasons Why Investors Should Love Regeneron's Q3 Update

Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q3 2021 Results - Earnings Call Transcript

Regeneron (REGN) beats on Q3 earnings while sales record strong year-over-year growth on the solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.

Regeneron (REGN) Q3 Earnings Beat, REGEN-COV Boosts Growth

iRhythm Technologies

Karyopharm Therapeutics

Tyra Biosciences

Could these health care stocks be buys on President Biden's latest vaccine mandate?

4 Health Care Stocks For Your November 2021 Watchlist

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) threw its hat into the earnings ring this morning, reporting third-quarter earnings and revenue that trounced Wall Street's estimates.

Regeneron Stock Slips Despite Earnings, Revenue Beat

New data for REGN5458 (BCMAxCD3 bispecific antibody) in patients with heavily pre-treated multiple myeloma to be highlighted in an oral presentation First data evaluating a combination therapy approach with pozelimab (C5 antibody) and Alnylam's cemdisiran (siRNA C5 inhibitor) in healthy volunteers Regeneron will host an investor webcast on Monday, December 13 to provide further updates across its hematology portfolio TARRYTOWN, N.Y., Nov. 4, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its diverse hematology program in blood cancers and disorders will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting from December 11-14 in Atlanta, GA.

Regeneron Presentations at ASH Highlight Expanding Clinical Research in Blood Cancers and Disorders

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is trading higher Thursday after the company announced better-than-expected third-quarter financial results. Regeneron reported quarterly adjusted earnings of $15.37 per share, which beat the estimate of $9.49 per share.

Why Regeneron Shares Are Rising Today

Regeneron Pharmaceuticals Inc's third-quarter profit nearly doubled on Thursday, helped by robust demand for its blockbuster drugs Dupixent to treat eczema and eye treatment Eylea.

Regeneron quarterly profit nearly doubles on strong demand for eczema drug

TARRYTOWN, N.Y., Nov. 4, 2021 /PRNewswire/ -- Third quarter 2021 revenues increased 51% to $3.45 billion versus third quarter 2020 including $804 million attributable to REGEN-COV ® (2) Third quarter 2021 EYLEA® U.S. net sales increased 12% versus third quarter 2020 to $1.47 billion Third quarter 2021 Dupixent® global net sales (3) , which are recorded by Sanofi, increased 55% to $1.66 billion versus third quarter 2020 Third quarter 2021 GAAP diluted EPS was $14.33 and non-GAAP diluted EPS (1) was $15.37 Positive results reported from four Phase 3 Dupixent studies; FDA expanded approval of Dupixent to include children aged 6 to 11 years with asthma Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2021 and provided a business update.

Regeneron Reports Third Quarter 2021 Financial and Operating Results

Regeneron Pharmaceuticals Inc. shares REGN, +2.09% rose 1.8% in premarket trade Thursday, after the company blew past estimates for the third quarter and said the U.S. government has ordered another 1.4 million doses of its COVID-19 antibody treatment. The company posted net income of $1.632 billion, or $14.33 a share, for the quarter, or almost double the $842 million, or $7.39 a share, in the year-earlier period.

Regeneron earnings boosted by $804 million in sales of COVID antibody treatment

Is (REGN) Outperforming Other Medical Stocks This Year?

Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?

Regeneron Pharmaceuticals (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Regeneron Pharmaceuticals (REGN) Ahead of Earnings?

Endo International

Novavax

Zoetis

Let us take a look at five drug/biotech companies due to release their quarterly results on Nov 4.

Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More

Regeneron's third-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.

Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings?

Pfizer

Vertex Pharmaceuticals

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates

Best Buy

CBRE Group

Celanese

Seagate Technology Holdings PLC

Seagate Technology (STX), Best Buy (BBY), Celanese Corporation (CE), CBRE Group (CBRE), and Regeneron Pharmaceuticals (REGN) are some stocks with high ROE to buy as the Fed tapering decision is expected soon.

Top 5 High ROE Stocks to Buy as Fed Tapering Looms Large

Regeneron's market value has climbed more than 1,000% in a decade.

Will Regeneron Be Worth More Than Amazon by 2030?

Regeneron (REGN) closed at $589.60 in the latest trading session, marking a -0.43% move from the prior day.

Regeneron (REGN) Stock Moves -0.43%: What You Should Know

The stock price has corrected sharply in recent months against the backdrop of which a multiple contraction has occurred. I think the dip was driven by a) Cathie Wood's transactions and b) declining new COVID-19 cases.

Regeneron Looks Oversold, Ready To Jump Up On Catalysts

Second Dupixent ® (dupilumab) Phase 3 e osinophilic e sophagitis t rial to d emonstrate s ignificant d isease i mprovements, u nderscoring r ole of t ype 2 i nflammation in t his c omplex d isease

Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease

Regeneron's (REGN) phase III study on Dupixent for treating adults with uncontrolled prurigo nodularis meets its primary and all secondary endpoints.

Regeneron (REGN) Dupixent Meets Goal in Prurigo Nodularis Study

ConocoPhillips

Chevron

Goldman Sachs

Exxon Mobil

We have narrowed down our search to five stocks that are members of any of the three major stock indexes. These are: GS, XOM, CVX, COP and REGN.

Major Stock Indexes Hit Record-High Level: 5 Top-Ranked Picks

Dupixent ® (dupilumab) is the f irst b iologic to s ignificantly reduce i tch and s kin l esions in P hase 3 t rial for p rurigo n odularis, demonstrating the role of t ype 2 inflammation in this disease

Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease

News for Regeneron Pharmaceuticals Stock (REGN)